CA
NZ
UK
AU
IND
US
Fate Therapeutics (Nasdaq: FATE) will also present updated clinical data from its RECLAIM-LN program evaluating FT819 in systemic lupus erythematosus at ACR from November 6 through 11. Phase 1 data presented at CCR West showed favorable tolerability with reduced conditioning, no Grade 3 or …
The additional buying brings ADAR1's total indirect beneficial holdings in InMed Pharmaceuticals (Nasdaq: INM), managed under Daniel Schneeberger, to 892,101 shares. The transactions were disclosed through standard beneficial ownership reporting requirements.
Despite the efficacy miss, Longeveron (Nasdaq: LGVN) noted that laromestrocel demonstrated a favorable safety profile in the trial, with no new safety signals identified in infants with this rare and severe congenital heart condition.
MN-166 is advancing through Phase 3 testing in amyotrophic lateral sclerosis, a progressive neurodegenerative disease with few treatment options, as well as in degenerative cervical myelopathy, a spinal cord condition. Roth MKM's initiation reflects enthusiasm for MediciNova's (Nasdaq: MNOV) core pipeline asset across both …
Business Overview:Recursion is an AI-driven, clinical-stage biotech that maps biology and chemistry data to accelerate drug discovery and its own therapeutic pipeline, generating most of itsTop Linethrough pharma collaborations rather than product sales.
Aethlon Medical (NASDAQ:AEMD) shares soared in pre-market trading Thursday after the company announced a definitive merger agreement for an all-stock transaction with North Immunology, a privately held biotechnology company developing bispecific antibodies for immune and inflammatory diseases. Aethlon Medical is a San Diego-based clinical-stage …
Denali Therapeutics (NASDAQ:DNLI) shares rebounded in pre-market trading Thursday after a roughly 16% pullback over the past month had left the stock trading well below analyst fair-value estimates near $35. Denali Therapeutics is a South San Francisco-based biopharmaceutical company pioneering therapies for neurodegenerative diseases, …
Illumina (NASDAQ:ILMN) shares climbed further in pre-market trading Thursday, extending a multi-day rally as investors positioned ahead of the company's addition to the S&P 500 index, effective before market open on September 21 as part of the index's quarterly rebalance. Illumina is a San …
Indivior (NASDAQ:INDV) shares rose in pre-market trading Thursday after the company declared a special cash dividend of $8.13 per share, contingent on the completion of its previously announced all-stock merger with Supernus Pharmaceuticals (NASDAQ:SUPN). Indivior is a specialty pharmaceutical company headquartered in North Chesterfield, …
Moderna (NASDAQ:MRNA) shares rose further in pre-market trading Thursday, extending a rally that began last week when the company and Merck (NYSE:MRK) announced that their personalized mRNA melanoma vaccine, intismeran autogene, met its primary endpoints in a Phase 3 trial. Moderna is a Cambridge, …
Please wait processing your request...